Joint Stock Co Grindeks, based in Latvia, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is DROPERIDOL USP, with a corresponding US DMF Number 22975.
Remarkably, this DMF maintains an Active status since its submission on July 16, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 15, 2013, and payment made on November 23, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II